[{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sibutramine Hydrochloride","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sibutramine Hydrochloride","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"New York State Psychiatric Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sibutramine Hydrochloride","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Sibutramine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Sibutramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Overweight.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 27, 2022

                          Lead Product(s) : Sibutramine Hydrochloride

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Sibutramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 14, 2012

                          Lead Product(s) : Sibutramine Hydrochloride

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          New York State Psychiatric Institute

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          New York State Psychiatric Institute

                          Country arrow
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Sibutramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 27, 2010

                          Lead Product(s) : Sibutramine Hydrochloride

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase IV

                          Sponsor : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank